NEW YORK - BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a biotech firm specializing in adult stem cell therapies for neurodegenerative diseases, is slated to provide a corporate update at the upcoming 17th Annual European Life Sciences CEO Forum. The event will take place in Zurich, Switzerland, on February 28 and 29, 2024.
The company's co-CEO, Dr. Stacy Lindborg, is scheduled to speak on February 28 at 13:40h CET in the Panorama Room, Track C, at the Hilton Zurich Airport Hotel. Additionally, Dr. Lindborg will engage in a panel discussion titled "Neuro Advances Panel: Highlighting the Main Opportunities" later that day at 17:20h.
Conference attendees will have the opportunity to meet with Dr. Lindborg and Mr. Chaim Lebovits, President and CEO of Brainstorm, in person on February 28 and 29. Virtual meetings are also scheduled for March 6 through 8.
BrainStorm is known for its development of the NurOwn® technology platform, which produces autologous MSC-NTF cells. These cells have been granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). The company has completed a Phase 3 trial in ALS, investigating the safety and efficacy of autologous MSC-NTF cells, which was supported by grants from the California Institute for Regenerative Medicine and the ALS Association and I AM ALS. Furthermore, BrainStorm conducted a Phase 2 trial in progressive MS with support from the National MS Society.
This news article is based on a press release statement from BrainStorm Cell Therapeutics Inc.
InvestingPro Insights
As BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) prepares to present at the 17th Annual European Life Sciences CEO Forum, current financial metrics from InvestingPro provide a snapshot of the company's market position. BrainStorm, with an adjusted market capitalization of $17.39 million USD, reflects a niche presence in the biotech sector. The company's financial health is a point of interest, with an adjusted P/E ratio for the last twelve months as of Q3 2023 standing at -1.05, indicating that investors are not valuing the company based on earnings at this time.
The stock's performance has been characterized by high volatility, with a 91.89% return over the last three months, yet a -86.35% return over the last year. This suggests significant fluctuations in investor sentiment and market valuation. Moreover, the InvestingPro Tips highlight that BrainStorm is quickly burning through cash and that its short-term obligations exceed its liquid assets, which could be a concern for investors considering the company's financial stability.
For those interested in a deeper analysis of BrainStorm's financials and stock performance, there are additional InvestingPro Tips available. These include insights on the company's gross profit margins, debt levels, and profitability projections. In total, there are 13 additional tips listed on InvestingPro, which can be accessed for those seeking to make an informed investment decision. To explore these further, investors are invited to use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
As BrainStorm continues its efforts in developing treatments for neurodegenerative diseases, these financial insights will be crucial for stakeholders tracking the company's progress and potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.